Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment.
Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment.
<iframe src="https://hindustansphere.com/embed/cluster/4ebdc59bb22822b5ad85092ea0ec1a3b7cc6aaf1" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth"></iframe>
Laurus Labs shares jumped 4.05% to Rs 1,666 in Monday’s trading session after the company reported a stellar performance for the June 2026 quarter. The rally was fueled by a 126% year-on-year surge in net profit and 29% revenue growth, driven by strong CDMO performance and steady demand for affordable medicines.According to the company’s regulatory filing, consolidated net profit for Q1FY27 stood at Rs 368 crore, compared with Rs 163 crore in the same quarter last year, marking a sharp 126% YoY…
